Healthegy Podcast – MedTech Talk: Ceterix CEO John McCutcheon is Writing a Different Ending with New Tech That Can Save the Meniscus

“I came to Ceterix with the belief that if we showed that we had clinical benefit, we would do something really special,” said John McCutcheon, Ceterix® Orthopaedics, president and CEO.

Listen to CEO John McCutcheon discuss his path to Ceterix Orthopaedics, the obstacles the company has overcome and how they are expanding the meniscus repair market with the NovoStitch® Plus Meniscal Repair System; realizing the company’s mission to “Save The Meniscus” for thousands of patients suffering with meniscal tear injuries.



About Ceterix Orthopaedics

Ceterix Orthopaedics develops surgical tools that fill unmet clinical needs for physicians who treat soft tissue joint injuries such as meniscus tears. Founded in 2010 with the vision of improving outcomes of arthroscopic procedures, Ceterix’s novel meniscal repair system enables surgeons to place suture patterns that were previously only possible in open procedures, or not at all.  The Novostitch® Pro Meniscal Repair System has received 510k clearance in the United States and is indicated for approximation of soft tissue in meniscal repair procedures. The company is based in Fremont, Calif., and is backed by investors Versant Ventures, 5AM Ventures and CRG. For more information, please visit and follow us at @ceterix on Twitter.

Media Contact:
Gary Metz

# # #

« Go Back